Interruption of Escherichia coli Heat-stable Enterotoxin-induced Guanylyl Cyclase Signaling and Associated Chloride Current in Human Intestinal Cells by 2-Chloroadenosine*

(Received for publication, August 6, 1996, and in revised form, October 15, 1996)

Scott J. Parkinson Dagger , Alexey E. Alekseev §, Luis A. Gomez §, Frank Wagner Dagger , Andre Terzic § and Scott A. Waldman Dagger

From the Dagger  Departments of Medicine and Pharmacology, Division of Clinical Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 and § Departments of Medicine and Pharmacology, Division of Cardiovascular Diseases, Mayo Clinic, Mayo Foundation, Rochester, Minnesota 55905

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Diarrhea induced by Escherichia coli heat-stable enterotoxin (STa) is mediated by a receptor guanylyl cyclase cascade. The present study establishes that an intracellular nucleotide-dependent pathway disrupts toxin-induced cyclic GMP (cGMP) production and the associated chloride (Cl-) flux that underlie intestinal secretion. Incubation of Caco 2 human intestinal epithelial cells with the nucleoside analog 2-chloroadenosine (2ClAdo) resulted in a concentration- and time-dependent inhibition of toxin-induced cGMP production. Inhibition of cGMP production correlated with the metabolic conversion of 2ClAdo to 2-chloroadenosine triphosphate. The effect of 2ClAdo did not reflect activation of adenosine receptors, inhibition of adenosine deaminase, or modification of the binding or distribution of STa receptors. Guanylyl cyclase activity in membranes prepared from 2ClAdo-treated cells was inhibited, in contrast to membranes from cells not exposed to 2ClAdo, demonstrating that inhibition of guanylyl cyclase C (GCC) was mediated by a noncompetitive mechanism. Treatment of Caco 2 cells with 2ClAdo also prevented STa-induced Cl- current. Application of 8-bromo-cGMP, the cell-permeant analog of cGMP, to 2ClAdo-treated cells reconstituted the Cl- current, demonstrating that inhibition of Cl- flux reflected selective disruption of ligand stimulation of GCC rather than the chloride channel itself. Thus, the components required for adenine nucleotide inhibition of GCC signaling are present in intact mammalian cells, establishing the utility of this pathway to elucidate the mechanisms regulating ST-dependent guanylyl cyclase signaling and intestinal fluid homeostasis. In addition, these data suggest that the adenine nucleotide inhibitory pathway may be a novel target to develop antisecretory therapy for enterotoxigenic diarrhea.


INTRODUCTION

Guanylyl cyclase C (GCC),1 the receptor for Escherichia coli heat-stable enterotoxin (STa) expressed in intestinal mucosa cells, is a member of the receptor guanylyl cyclase family that possesses receptor and catalytic domains on a single transmembrane protein (1, 2). Occupancy by STa of the extracellular receptor domain induces catalytic conversion of intracellular GTP to cyclic GMP (cGMP), resulting in sequential alterations in epithelial cell chloride flux, electrolyte and fluid secretion, and diarrhea (3, 4, 5, 6, 7). Interventions that specifically interrupt the STa-induced GCC-mediated signal sequence have not been defined. In cell-free systems, GCC is allosterically inhibited by 2-substituted adenine nucleotides (8, 9). Yet, the impermeance of intact cells to phosphorylated nucleotides and the absence of endogenous 2-substituted nucleotides has precluded the disruption of STa-induced signaling in intestinal cells through this inhibitory pathway. However, intestinal cells express transporters, which carry 2-substituted nucleosides into the cytosol, and adenosine kinase, which catalyzes conversion of 2-substituted nucleosides into 2-substituted nucleotides (10). The present studies examine whether that mechanism can be exploited to interrupt transmembrane signaling and alterations in chloride flux induced by STa in intact intestinal epithelial cells.


EXPERIMENTAL PROCEDURES

Cyclic GMP Accumulation in Intact Cells

Caco 2 cells, well differentiated human colon carcinoma cells, were seeded in 24-well plates, allowed to reach confluence, and grown for an additional 14-21 days to ensure differentiation of these cells into colonic enterocytes. HEK293 cells, human embryonic kidney cells expressing recombinant GCC, were seeded in 24-well plates, allowed to reach confluence, and used for assays at least 5 days after seeding (1, 11). Cells were incubated in OPTI-MEM serum-free media (Life Technologies, Inc.) (0.5 ml/well) containing indicated concentrations of the test substances for the given period of time. Cells were washed three times with OPTI-MEM, then incubated in OPTI-MEM (0.2 ml/well) containing 0.12 mM isobutylmethylxanthine to inhibit endogenous phosphodiesterases for 10 min. STa was added to a final concentration of 0.5 µM for 10 min. Trichloroacetic acid (0.2 ml of 12% solution) was added to the wells to lyse the cells and terminate the reaction. Well contents were collected and centrifuged 15 min in a microcentrifuge to separate pellet and supernatant (8). The supernatant was collected, the trichloroacetic acid was removed by ether extraction, and the sample was used for cGMP determination by radioimmunoassay (12). Pellets were saved for determination of protein content by the method of Bradford (Bio-Rad).

Guanylyl Cyclase Assay

Cells were treated in OPTI-MEM media containing test substances as described above. Wells were washed three times with a Tris buffer (50 mM, pH 7.5) containing 1 mM EDTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride (TED buffer) (8, 9). Cells were collected in TED and homogenized on ice. Homogenates were centrifuged at 100,000 × g for 60 min at 4 °C. Membranes were resuspended in TED with a final concentration of approximately 1 mg of protein/ml. Membranes were incubated at 37 °C for 5 min in 0.1 ml of a Tris buffer (50 mM, pH 7.5) containing 500 mM isobutylmethylxanthine, 7.5 mM creatine phosphate/20 mM creatine phosphokinase and either 10 mM MgGTP and 1 mM STa or 1 mM MnGTP. Enzyme reaction was terminated by addition of 0.5 ml NaAc (50 mM, pH 4.0) and boiling for 5 min. Cyclic GMP was quantified by radioimmunoassay as described previously (12).

STa Binding Assay

Following membrane preparation as described above, 30 µl of membrane were incubated in 50 mM Tris, pH 7.6, containing 1 mM EDTA, 150 mM KCl, 0.1% bacitracin, and 0.67 mM cystamine (binding buffer). Binding was initiated by the addition of 125I-labeled STa (10-13 to 5 × 10-8 M) (13). Reactions were incubated for 120 min at 37 °C and terminated by filtration on Whatman GF/B glass fiber filters presoaked with 0.3% polyethyleneimine. Filters were washed three times with 5 ml of buffer containing 150 mM NaCl, 20 mM phosphate (pH 7.2), and 1 mM EDTA at 4 °C. Specific binding was determined by subtracting nonspecific binding (1000-fold excess of cold STa) from total binding. Assays were performed in quadruplicate. Analysis of ligand binding was performed using CIGALE, written by M. Bordes (Sophia Antipolis, France; Ref. 13).

Nucleoside Uptake Assays

Cells were incubated with [8-3H]2Cl-adenosine (2ClAdo; 1 µM) in OPTI-MEM, and uptake was terminated with unlabeled 2ClAdo (1 mM) at indicated times. Washed cells were lysed with 6% trichloroacetic acid, extracts were centrifuged to collect supernatants, and radioactivity in supernatants was quantified. Nonspecific values were determined from experiments where the addition of cold 2ClAdo preceded addition of [8-3H]-2ClAdo. These values were subtracted from totals to obtain specific values (10). Pellets were used to determine protein content, and intracellular volumes were calculated using 3.66 µl/mg protein as reference (14). In unpublished experiments, to determine cation dependence, a buffer composed of 120 mM Na+ or K+, 20 mM Tris (pH 7.4), 3 mM Na2HPO4 or K2HPO4, 1 mM MgCl2, and 1.8 mM CaCl2 was used. No significant difference in the rate of uptake could be observed using this buffer or OPTI-MEM. Because all of the other experiments used OPTI-MEM, uptake experiments were done using OPTI-MEM.

High-performance Liquid Chromatography Determination of Nucleotide Level

Cells were incubated as described above with 1 mM 2ClAdo for the indicated times and extracted with trichloroacetic acid; resulting supernatants were chromatographed on a Waters 12.5 nm, 10 µm µBondpack 3.9 × 300-mm C18 column, preequilibrated with a mobile phase (buffer A) containing 10 mM tetrabutylammonium hydroxide, 10 mM KH2PO4, and 0.25% MeOH, pH 7.0 (15). A step gradient was used with mobile phase buffer B (2.8 mM tetrabutylammonium hydroxide, 100 mM KH2PO4, and 30% MeOH, pH 5.5). The gradient was programmed as follows: 0-15 min, 100% buffer A; 20 min, 90% buffer A, 10% buffer B; 25 min, 70% buffer A, 30% buffer B; 40 min, 63% buffer A, 37% buffer B; 55 min, 55% buffer A, 45% buffer B; 75 min, 25% buffer A, 75% buffer B; 85 min, 0% buffer A, 100% buffer B for 10 min; at 125 min, 100% buffer A. Identification and quantification were achieved by comparing retention times of unknowns to standards. Intracellular nucleotide concentrations were calculated using the high-performance liquid chromatography-quantified molar amounts of nucleotide.

Perforated Whole-cell Patch Clamp Recordings of Caco 2 Cells

The perforated mode of the whole-cell patch clamp recording, which limits dialysis of intracellular signaling molecules, was applied to Caco 2 cells (16, 17). Membrane potential was controlled through the electrical access obtained by membrane perforation induced by amphotericin B (240 µg/ml) in the localized area under the patch pipette (3-5 megaohms). The bath solution contained 136.5 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.53 mM MgCl2, 5.5 mM glucose, and 5.5 mM Hepes-NaOH, pH 7.4. The pipette solution contained 140 mM K+-gluconate, 5 mM MgCl2, 1 mM EGTA, and 5 mM Hepes-KOH, pH 7.3. Voltage clamp recordings were obtained using a patch-clamp amplifier (Axopatch 1-C, Axon Instruments), and data were acquired and analyzed using BioQuest software (17).


RESULTS AND DISCUSSION

Treatment of either Caco 2 cells natively expressing GCC or HEK293 cells heterologously expressing recombinant GCC with the nucleoside 2ClAdo, a metabolic precursor of 2ClATP, suppressed STa-induced cGMP accumulation (Fig. 1a). The effect of 2ClAdo was concentration (Ki = 101 ± 21 µM; Fig. 1b)- and time-dependent (t1/2 of 10 h; Fig. 1c). The 2ClAdo effect appeared temporally biphasic, because inhibition of STa-induced cGMP accumulation was preceded by a transient increase in STa-induced cGMP accumulation at early (t <=  4 h) timepoints (Fig. 1c). Although the mechanisms underlying this initial transient rise in cGMP remain unclear, 2ClAdo is a potent ligand for adenosine receptors, and activation of other signaling mechanisms through these receptors could activate GCC (18). There was no significant difference in the number of cells or the amount of recovered protein in control or 2ClAdo-treated cells. Removal of 2ClAdo restored STa-dependent cGMP accumulation (t1/2 of 6 h; Fig. 1c, inset), suggesting that inhibition of cGMP synthesis did not reflect cell death.


Fig. 1. a, 2ClAdo treatment prevents STa-induced cGMP accumulation in human intestinal Caco 2 cells (endogenously expressing GCC) and HEK293 human embryonic kidney cells (transfected with rat GCC cDNA). Suppression of STa-induced cGMP accumulation in intestinal cells as a function of 2ClAdo concentration (b) and time of exposure (c) or recovery (c, inset) is shown. Caco 2 or HEK293 cells were incubated for 20 h in the presence or absence of 2ClAdo (1 mM) in 24-well plates in serum-free culture medium (OPTI-MEM I, Life Technologies, Inc.). In a (n = 3; means are shown; bars, S.E.) and b (representative of six experiments), cells were washed and equilibrated for 10 min in serum-free medium containing 120 µM isobutylmethylxanthine to inhibit phosphodiesterase activity. Under these conditions, cGMP accumulation reflects synthesis by GCC only. Subsequently, STa (0.5 µM) was added, and incubations continued for 10 min. Production of cGMP and protein were quantified by radioimmuno- and colorimetric assays, respectively. In c (representative of three experiments), Caco 2 cells were treated with 2ClAdo for the indicated times with serum-free culture medium containing 1 mM 2ClAdo. Cells were washed and then incubated in serum-free culture medium containing isobutylmethylxanthine for 10 min. STa (0.5 µM) was added, and cGMP accumulation was quantified. In the inset, Caco 2 cells were treated for 20 h with 1 mM 2ClAdo. The medium was removed, and cells were washed and then incubated with serum-free medium for the indicated times, following which cGMP accumulation in response to STa was quantified, as described above.
[View Larger Version of this Image (26K GIF file)]


Adenosine analogs such as 2ClAdo are potent agonists for extracellular purinergic receptors. Furthermore, 2ClAdo is a low potency inhibitor of adenosine deaminase (19), an enzyme that regulates intracellular nucleotide concentrations. However, the effects of 2ClAdo could not be mimicked by N-ethylcarboxamidoadenosine, a purinergic P1 agonist with similar receptor potencies to 2ClAdo, nor by reversible (erythro-9-(2-hydroxy-3-nonyl)adenine) or irreversible (deoxycoformycin) adenosine deaminase inhibitors (Fig. 2a; Ref. 20). These data suggest that 2ClAdo-dependent inhibition of GCC signaling does not reflect the potency of this nucleoside for purinergic receptors or competitive inhibition of adenosine deaminase.


Fig. 2. In a, the purinoceptor agonist, N-ethylcarboxamidoadenosine (NECA) and adenosine deaminase inhibitors, deoxycoformycin (DCF) and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), did not mimic the effect of 2ClAdo on STa-induced cGMP accumulation in Caco 2 cells (n = 3; bars, S.E.). In b, treatment of Caco 2 cells with 2ClAdo did not significantly alter STa receptor binding characteristics. A representative experiment demonstrating that Caco 2 cells not treated (-) or treated with 2ClAdo for 20 h (+) exhibited high and low affinity STa binding is shown. c, time course of specific uptake of [8-3H]2ClAdo by Caco 2 cells (n = 3; bars, S.E.).
[View Larger Version of this Image (29K GIF file)]


125I-labeled STa bound to membranes prepared from Caco 2 cells incubated in the absence and presence of 2ClAdo in a concentration-dependent and saturable fashion. Scatchard analyses yielded curvilinear isotherms, suggesting the presence of high and low affinity ligand-binding sites in both 2ClAdo-treated and control cells (Fig. 2b). Equilibrium binding parameters derived from Scatchard analyses suggested that 2ClAdo treatment did not significantly alter the number or affinity of ligand receptors (Fig. 2b). Thus, in membranes from control and treated cells, respectively, the numbers of high affinity (Bmax, 2.1 ± 1.3 versus 2.9 ± 2.1 fmol/mg of protein) and low affinity (Bmax, 0.03 ± 0.02 versus 0.08 ± 0.05 pmol/mg of protein) binding sites were closely comparable. Similarly, the affinities of high (KD, 0.9 ± 0.5 versus 6.5 ± 6.1 pM) and low (KD, 1.3 ± 1.1 versus 4.5 ± 2.0 nM) affinity binding sites compared favorably in membranes from control and treated cells, respectively. Equilibrium binding parameters (values ± S.E.) obtained in the present studies compare closely with those reported previously for high and low affinity STa binding sites (13, 21, 22, 23). Similarly, 2ClAdo neither decreased the number of 125I-labeled STa binding sites on the cell surface nor increased the rate of 125I-labeled STa internalization in intact cells (data not shown; Ref. 24). Therefore, inhibition of GCC signaling could not be attributed to alterations in distribution, sequestration, or ligand binding characteristics of the receptor.

Caco 2 cells incorporated [8-3H]2ClAdo in a time-dependent fashion (Fig. 2c). Uptake of [8-3H]2ClAdo was not dependent on extracellular Na+, suggesting that intracellular accumulation was mediated by an equilibrative nucleoside transport mechanism (10). Iodotubercidin, an adenosine kinase inhibitor, did not alter the initial rate of uptake but prevented further increases in intracellular [8-3H]2ClAdo (data not shown). These data suggest that cellular nucleoside accumulation was dependent on transport coupled to metabolic conversion to a phosphorylated product (10, 20).

Although 2ClAdo inhibited STa-induced cGMP accumulation in intact cells, this nucleoside did not suppress the activity of GCC in intestinal cell membranes (Fig. 3a). However, membranes prepared from intact cells pretreated with 2ClAdo did exhibit persistent inhibition of GCC (Fig. 3b). These data further suggest that 2ClAdo undergoes intracellular metabolic conversion into the proximal allosteric inhibitor of GCC. High-performance liquid chromatography analysis of 2ClAdo-treated human intestinal cells revealed time-dependent accumulation of 2ClATP (Fig. 3c), which correlated closely with nucleoside inhibition of STa-induced cGMP accumulation. In contrast to 2ClAdo (Fig. 3a), 2ClATP directly inhibited the activity of GCC in intestinal cell membranes (Fig. 3c, inset). Iodotubercidin, a competitive inhibitor of phosphorylation of 2ClAdo by adenosine kinase, decreased the potency of 2ClAdo to inhibit STa-induced cGMP production (Fig. 3d; Ref. 20). Thus, 2ClAdo inhibits STa-induced cGMP accumulation in intact cells following intracellular phosphorylation by adenosine kinase, ultimately to 2ClATP, an effective allosteric inhibitor of GCC (8, 9).


Fig. 3. In a, direct application of 2ClAdo (1 mM) to membranes isolated from Caco 2 cells failed to inhibit guanylyl cyclase (n = 3; bars, S.E.). Guanylyl cyclase was assessed in membranes using 1 mM Mn2+-GTP in the presence and absence of 1 mM 2ClAdo. In b, pretreatment of intact cells with 2ClAdo (1 mM, 20 h) produced persistent inhibition of STa-stimulated guanylyl cyclase in membranes isolated from these cells (n = 3; bars, S.E.). STa (1 µM)-stimulated guanylyl cyclase (10 mM Mg2+-GTP) in membranes of control or 2ClAdo (1 mM, 20 h) treated cells. In c, 2ClAdo and 2ClATP accumulated in a time-dependent fashion in Caco 2 cells treated with 2ClAdo (n = 3). In the absence of 2ClAdo pretreatment (time 0), endogenous pools of 2ClAdo and 2ClATP were undetectable. At 1 h, 2ClAdo reached an apparent steady-state intracellular concentration, whereas 2ClATP continued to rise over the 20-h time course of measurement. Throughout 2ClAdo treatment, the concentration of intracellular GTP, the substrate for GCC, did not change. In the inset, direct application of 2ClATP to membranes isolated from Caco 2 cells inhibited guanylyl cyclase (n = 3; bars, S.E.). The effects of 2ClATP (1 mM) on guanylyl cyclase activity was quantified as described in a. In d, iodotubericidin (20 µM), a competitive inhibitor of adenosine kinase, induced a rightward shift in the concentration dependence of 2ClAdo to inhibit STa-induced cGMP accumulation (representative of three experiments). Cyclic GMP accumulation was quantified as in Fig. 1b.
[View Larger Version of this Image (44K GIF file)]


To determine the consequence of disrupting cGMP accumulation with 2ClAdo on STa-induced postreceptor signals, alterations in chloride current were examined in human intestinal cells. In Caco 2 cells, STa induced an outward current (135 ± 33 pA at a membrane potential of +10 mV, n = 4), which was suppressed by removal of extracellular chloride or by the addition of glyburide (Fig. 4a). The selectivity for Cl- outward rectification reversal potential at -70 mV and pharmacological properties (Fig. 4, a and a1) were all consistent with the presumed role of the cystic fibrosis transmembrane conductance regulator in mediating STa-induced alterations in chloride conductance in intestinal cells (25, 26, 27, 28). However, in Caco 2 cells treated with 2ClAdo, STa could no longer induce a chloride current (Fig. 4, b and c). Yet, in the same 2ClAdo-treated cells, 8-bromo cGMP, a membrane-permeant cGMP analog (6), produced an outward current that was abolished by removal of extracellular chloride (Fig. 4b). Thus, 2ClAdo treatment specifically blocked STa-dependent signaling by inhibiting GCC and accumulation of cGMP, rather than altering the ability of cGMP to generate chloride currents.


Fig. 4. 2ClAdo treatment prevents STa-induced Cl- current in Caco-2 cells. In a, in the absence of 2ClAdo treatment, STa induced Cl- current. Upper row, time course of steady-state outward current recorded at +10 mV following a depolarizing pulse from the holding potential (-40 mV). The STa-induced current, which reached apparent steady-state within 10-15 min, was reversibly suppressed by replacement of extracellular Cl- with methansulfonate. Lower row, currents elicited by rectangular 1000-ms pulses from a holding potential of -40 mV to potentials from -90 to +50 mV and recorded under the following conditions: before treatment, in STa (100 nM), in STa following removal of Cl-, in STa following return of Cl- to the bathing solution, and in STa following application of glyburide (100 µM). a1, voltage-current properties of the STa-induced current obtained by subtraction of currents recorded in the absence and presence of STa. Voltage-current relationship plotted for steady-state (at 900 ms) values of the STa-induced current with an estimated reversal potential at -70 mV. H.P. refers to the value of the holding potential. In b, following treatment of cells with 2ClAdo (1 mM, 20 h), STa failed to induce a Cl- current. Upper row, time course of the steady-state outward current recorded as in a. Although STa was without effect, 8-bromo-cGMP applied to the extracellular solution activated an outward current that was suppressed by removal of extracellular Cl-. Lower row, currents elicited as in a were recorded under the following conditions: before treatment, in STa (100 nM), in 8-bromo-cGMP (5 mM), and in 8-bromo-cGMP following replacement of Cl- by methansulfonate. In c, STa-induced current in the absence (n = 4) of and following (n = 4) 2ClAdo treatment (1 mM, 20 h). Values were obtained by subtracting current amplitudes recorded prior to and following the addition of STa (100 nM) using the protocol described in a; bars, S.E.
[View Larger Version of this Image (29K GIF file)]


The present studies establish an intracellular nucleotide-dependent pathway for inhibition of GCC signaling in intact human intestinal cells (Fig. 5). Uptake and phosphorylation of 2ClAdo results in accumulation of 2ClATP, which inhibits STa activation of guanylyl cyclase, accumulation of cGMP, and subsequent chloride fluxes mediating toxin-induced diarrhea. These data demonstrate that the components required for 2-substituted adenine nucleotide inhibition of GCC signaling are present in intact mammalian cells, establishing this pathway as a tool for elucidating the molecular mechanisms regulating GCC and intestinal fluid homeostasis. In addition, these data suggest that the adenine nucleotide inhibitory pathway may be a novel target for developing antisecretory therapy to treat enterotoxigenic diarrhea.


Fig. 5. Molecular pathway by which 2ClAdo inhibits STa-induced GCC signaling and chloride current in human intestinal cells. Uptake of 2ClAdo by intestinal cells (Step 1) leads to adenosine kinase-mediated conversion of the nucleoside (Step 2) and intracellular accumulation of the nucleotide 2ClATP (Step 3). In turn, 2ClATP allosterically inhibits STa activation of GCC (Step 4), preventing cGMP accumulation (Step 5), and phosphorylation of CFTR chloride channels (Step 6), consequently interrupting STa-induced cGMP-dependent chloride flux (Step 7).
[View Larger Version of this Image (71K GIF file)]



FOOTNOTES

*   This work was supported by grants from the National Institutes of Health, National Science Foundation, the Elsa U. Pardee Foundation, the W. W. Smith Charitable Trust, the Pharmaceutical Research and Manufacturers of America Foundation, Inc., the American Heart Association, the Harrington Professorship Fund, the Miami Heart Research Institute, COLCIENCIAS, and Targeted Diagnostics and Therapeutics, Inc. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Depts. of Medicine and Pharmacology, Division of Clinical Pharmacology, Thomas Jefferson University, 1100 Walnut St., MOB 813, Philadelphia, PA 19107. Tel.: 215-955-6608; Fax: 215-955-5681; E-mail: waldmans{at}jeflin.tju.edu.
1    The abbreviations used are: GCC, guanylyl cyclase C; cGMP, cyclic GMP; STa, E. coli heat-stable enterotoxin; 2ClAdo, 2-chloroadenosine; 2ClATP, 2-chloroadenosine triphosphate.

Acknowledgments

We thank Drs. Stephanie Schulz and David Garbers for the generous gift of HEK293 cells stably expressing rat GCC and Dr. D. C. Robertson for the generous gift of ST.


REFERENCES

  1. Schulz, S., Green, C. K., Yuen, P. S. T., and Garbers, D. L. (1990) Cell 63, 941-948 [Medline] [Order article via Infotrieve]
  2. Garbers, D. L., and Lowe, D. G. (1994) J. Biol. Chem. 269, 30741-30744 [Free Full Text]
  3. Rohde, J. E. (1984) Rev. Infect. Dis. 6, 840-854 [Medline] [Order article via Infotrieve]
  4. 4, 1-5Gold, R. (1988) Drugs 36, Suppl. 4, 1-5
  5. Field, M., Graf, L. H., Laird, W. J., and Smith, P. L. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 2800-2804 [Abstract]
  6. Hughes, J. M., Murad, F., Chang, B., and Guerrant, R. L. (1978) Nature 271, 755-756 [Medline] [Order article via Infotrieve]
  7. Huott, F. A., Liu, W., McRoberts, J. A., Giannella, R. A., and Dharmsathaphorn, K. (1988) J. Clin. Invest. 82, 514-523 [Medline] [Order article via Infotrieve]
  8. Parkinson, S. J., and Waldman, S. A. (1996) Biochemistry 35, 3213-3221 [CrossRef][Medline] [Order article via Infotrieve]
  9. Parkinson, S. J., Carrithers, S. L., and Waldman, S. A. (1994) J. Biol. Chem. 269, 22683-22690 [Abstract/Free Full Text]
  10. Belt, J. A., Marina, N. M., Phelps, D. A., and Crawford, C. R. (1993) Adv. Enz. Reg. 33, 235-252 [CrossRef][Medline] [Order article via Infotrieve]
  11. Vandrager, A. B., van der Wiel, E., Hom, M. L., Luthjens, L. H., and de Jonge, H. R. (1994) J. Biol. Chem. 269, 16409-16415 [Abstract/Free Full Text]
  12. Patrinellis, A. C., and Waldman, S. A. (1994) Biochim. Biophys. Acta 1243, 143-150
  13. Deshmane, S. P., Carrithers, S. L., Parkinson, S. J., Crupper, S. S., Robertson, D. C., and Waldman, S. A. (1995) Biochemistry 34, 9095-9102 [Medline] [Order article via Infotrieve]
  14. Blais, A., Bissonnette, P., and Berteloot, A. (1987) J. Membr. Biol. 99, 113-125 [Medline] [Order article via Infotrieve]
  15. Di Pierro, D., Tavazzi, B., Perno, C. F., Bartolini, M., Balestra, E., Calio, R., Giardina, B., and Lazzarino, G. (1995) Anal. Biochem. 231, 407-412 [CrossRef][Medline] [Order article via Infotrieve]
  16. Alekseev, A. E., Markevich, N. I., Korystova, A. F., Terzic, A., and Kokoz, Y. M. (1996) Biophys. J. 70, 786-797 [Abstract]
  17. Alekseev, A. E., Jovanovic, A., Lopez, J. R., and Terzic, A. (1996) J. Mol. Cell. Cardiol. 28, 1193-1202 [CrossRef][Medline] [Order article via Infotrieve]
  18. Crane, J. K., Wehner, M. S., Bolen, E. J., Sando, J. J., Linden, J., Guerrant, R. L., and Sears, C. L. (1992) Infect. Immun. 60, 5004-5012 [Abstract]
  19. Simon, L. N., Bauer, R. J., Tolman, R. L., and Robins, R. K. (1970) Biochemistry 9, 573-577 [Medline] [Order article via Infotrieve]
  20. Daly, J. W. (1982) J. Med. Chem. 25, 197-207 [Medline] [Order article via Infotrieve]
  21. Hugues, M., Crane, M., Hakki, S., O'Hanley, P., and And Waldman, S. A. (1991) Biochemistry 30, 10738-10745 [Medline] [Order article via Infotrieve]
  22. Crane, M., Hugues, M., O'Hanley, P., and Waldman, S. A. (1992) Mol. Pharmacol. 41, 1073-1080 [Abstract]
  23. Hakki, S., Robertson, D. C., and Waldman, S. A. (1993) Biochim. Biophys. Acta 1152, 1-8 [Medline] [Order article via Infotrieve]
  24. Urbanski, R. W., Carrithers, S. L., and Waldman, S. A. (1995) Biochim. Biophys. Acta 1245, 29-36 [Medline] [Order article via Infotrieve]
  25. Sheppard, D. N., and Welsh, M. J. (1992) J. Gen. Physiol. 100, 573-591 [Abstract]
  26. Chao, A. C., de Sauvage, F. J., Dong, Y. J., Wagner, J. A., Goeddel, D. V., and Gardner, P. (1994) EMBO J. 13, 1065-1072 [Abstract]
  27. Forte, L. R., Thorne, P. K., Eber, S. L., Krause, W. J., Freeman, R. H., Francis, S. H., and Corbin, J. D. (1992) Am. J. Physiol. 263, C607-C615 [Abstract/Free Full Text]
  28. Tien, X. Y., Brasitus, T. A., Kaetzel, M. A., Dedman, J. R., and Nelson, D. J. (1994) J. Biol. Chem. 269, 51-54 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.